U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06972537) titled 'A Study on the Infusion Regimen of Piperacillin-Tazobactam in Patients Aged 65 and Older With Pneumonia' on April 16.
Brief Summary: Pneumonia is characterized by high incidence and mortality rates in elderly patients (>=65 years old). Piperacillin-tazobactam, as a broad-spectrum antibiotic, has its therapeutic efficacy and safety potentially influenced by the infusion regimen. However, research on infusion regimens specifically targeting the elderly population is currently limited. In our preliminary dose simulation, under the pharmacokinetic/pharmacodynamic (PK/PD) target of achieving a free drug concentration time percentage above...